Glucose-Regulated Protein 94 (GRP94): A Novel Regulator of Insulin-Like Growth Factor Production

被引:20
作者
Argon, Yair [1 ,2 ]
Bresson, Sophie E. [3 ]
Marzec, Michal T. [3 ]
Grimberg, Adda [4 ,5 ]
机构
[1] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Cell Pathol, Philadelphia, PA 19104 USA
[3] Univ Copenhagen, Dept Biomed Sci, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark
[4] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA
关键词
glucose regulated protein (GRP) 94; insulin-like growth factor; obligate chaperone; I IGF-I; TOLL-LIKE RECEPTORS; ENDOPLASMIC-RETICULUM; CHAPERONE ACTIVITY; REFERENCE VALUES; SHORT STATURE; C-ELEGANS; BINDING; HORMONE; GP96;
D O I
10.3390/cells9081844
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mammals have two insulin-like growth factors (IGF) that are key mediators of somatic growth, tissue differentiation, and cellular responses to stress. Thus, the mechanisms that regulate the bioavailability of IGFs are important in both normal and aberrant development. IGF-I levels are primarily controlled via the growth hormone-IGF axis, in response to nutritional status, and also reflect metabolic diseases and cancer. One mechanism that controls IGF bioavailablity is the binding of circulating IGF to a number of binding proteins that keep IGF in a stable, but receptor non-binding state. However, even before IGF is released from the cells that produce it, it undergoes an obligatory association with a ubiquitous chaperone protein, GRP94. This binding is required for secretion of a properly folded, mature IGF. This chapter reviews the known aspects of the interaction and highlights the specificity issues yet to be determined. The IGF-GRP94 interaction provides a potential novel mechanism of idiopathic short stature, involving the obligatory chaperone and not just IGF gene expression. It also provides a novel target for cancer treatment, as GRP94 activity can be either inhibited or enhanced.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 91 条
[1]   GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults [J].
Allen, D. B. ;
Backeljauw, P. ;
Bidlingmaier, M. ;
Biller, B. M. K. ;
Boguszewski, M. ;
Burman, P. ;
Butler, G. ;
Chihara, K. ;
Christiansen, J. ;
Cianfarani, S. ;
Clayton, P. ;
Clemmons, D. ;
Cohen, P. ;
Darendeliler, F. ;
Deal, C. ;
Dunger, D. ;
Erfurth, E. M. ;
Fuqua, J. S. ;
Grimberg, A. ;
Haymond, M. ;
Higham, C. ;
Ho, K. ;
Hoffman, A. R. ;
Hokken-Koelega, A. ;
Johannsson, G. ;
Juul, A. ;
Kopchick, J. ;
Lee, P. ;
Pollak, M. ;
Radovick, S. ;
Robison, L. ;
Rosenfeld, R. ;
Ross, R. J. ;
Savendahl, L. ;
Saenger, P. ;
Sorensen, H. Toft ;
Stochholm, K. ;
Strasburger, C. ;
Swerdlow, A. ;
Thorner, M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (02) :P1-P9
[2]   Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94 [J].
Ansa-Addo, Ephraim A. ;
Thaxton, Jessica ;
Hong, Feng ;
Wu, Bill X. ;
Zhang, Yongliang ;
Fugle, Caroline W. ;
Metelli, Alessandra ;
Riesenberg, Brian ;
Williams, Katelyn ;
Gewirth, Daniel T. ;
Chiosis, Gabriela ;
Liu, Bei ;
Li, Zihai .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (25) :2765-2778
[3]   Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production [J].
Barton, Elisabeth R. ;
Park, SooHyun ;
James, Jose K. ;
Makarewich, Catherine A. ;
Philippou, Anastassios ;
Eletto, Davide ;
Lei, Hanqin ;
Brisson, Becky ;
Ostrovsky, Olga ;
Li, Zihai ;
Argon, Yair .
FASEB JOURNAL, 2012, 26 (09) :3691-3702
[4]   Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review [J].
Bergman, Daniel ;
Halje, Matilda ;
Nordin, Matilda ;
Engstrom, Wilhelm .
GERONTOLOGY, 2013, 59 (03) :240-249
[5]   The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells [J].
Biswas, Chhanda ;
Sriram, Uma ;
Ciric, Bogoljub ;
Ostrovsky, Olga ;
Gallucci, Stefania ;
Argon, Yair .
INTERNATIONAL IMMUNOLOGY, 2006, 18 (07) :1147-1157
[6]   Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors [J].
Blachere, NE ;
Srivastava, PK .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (06) :349-355
[7]  
BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610
[8]   Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement [J].
Brioude, Frederic ;
Kalish, Jennifer M. ;
Mussa, Alessandro ;
Foster, Alison C. ;
Bliek, Jet ;
Ferrero, Giovanni Battista ;
Boonen, Susanne E. ;
Cole, Trevor ;
Baker, Robert ;
Bertoletti, Monica ;
Cocchi, Guido ;
Coze, Carole ;
De Pellegrin, Maurizio ;
Hussain, Khalid ;
Ibrahim, Abdulla ;
Kilby, Mark D. ;
Krajewska-Walasek, Malgorzata ;
Kratz, Christian P. ;
Ladusans, Edmund J. ;
Lapunzina, Pablo ;
Le Bouc, Yves ;
Maas, Saskia M. ;
Macdonald, Fiona ;
Ounap, Katrin ;
Peruzzi, Licia ;
Rossignol, Sylvie ;
Russo, Silvia ;
Shipster, Caroleen ;
Skorka, Agata ;
Tatton-Brown, Katrina ;
Tenorio, Jair ;
Tortora, Chiara ;
Gronskov, Karen ;
Netchine, Irene ;
Hennekam, Raoul C. ;
Prawitt, Dirk ;
Tumer, Zeynep ;
Eggermann, Thomas ;
Mackay, Deborah J. G. ;
Riccio, Andrea ;
Maher, Eamonn R. .
NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (04) :229-249
[9]   Keeping IGF-II under control: Lessons from the IGF-II-IGF2R crystal structure [J].
Brown, James ;
Jones, E. Yvonne ;
Forbes, Briony E. .
TRENDS IN BIOCHEMICAL SCIENCES, 2009, 34 (12) :612-619
[10]   Insulin-like growth factor binding protein proteolysis [J].
Bunn, RC ;
Fowlkes, JL .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (04) :176-181